Cesca Therapeutics Inc. (KOOL) Can’t Be More Safe. Trades Significantly Higher – Invest Tribune

The stock of Cesca Therapeutics Inc. (NASDAQ:KOOL) is a huge mover today! The stock increased 19.51% or $1.04 during the last trading session, reaching $6.37. About 466,735 shares traded or 150.06% up from the average. Cesca Therapeutics Inc. (NASDAQ:KOOL) has declined 25.50% since September 23, 2018 and is downtrending. It has underperformed by 25.50% the S&P500.The move comes after 5 months positive chart setup for the $15.39 million company. It was reported on Sep, 23 by Barchart.com. We have $6.69 PT which if reached, will make NASDAQ:KOOL worth $769,600 more.

Analysts await Cesca Therapeutics Inc. (NASDAQ:KOOL) to report earnings on November, 13. They expect $-0.15 earnings per share, up 87.50 % or $1.05 from last years $-1.2 per share. After $-0.47 actual earnings per share reported by Cesca Therapeutics Inc. for the previous quarter, Wall Street now forecasts -68.09 % EPS growth.

More notable recent Cesca Therapeutics Inc. (NASDAQ:KOOL) news were published by: Seekingalpha.com which released: AXP II deal in India fails to lift Cesca, shares down 7% premarket Seeking Alpha on June 25, 2019, also Benzinga.com with their article: 30 Stocks Moving in Mondays Pre-Market Session Benzinga published on September 09, 2019, Globenewswire.com published: Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series Products That Provide Automated, Closed System Cellular Processing GlobeNewswire on April 24, 2018. More interesting news about Cesca Therapeutics Inc. (NASDAQ:KOOL) were released by: Finance.Yahoo.com and their article: The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering Yahoo Finance published on September 20, 2019 as well as Prnewswire.coms news article titled: ThermoGenesis Corp Signs Strategic Supply Agreement with Orthohealing Center Management to Provide its PXP Point-of-Care System to Orthohealing Method Physician Members PRNewswire with publication date: February 01, 2019.

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company has market cap of $15.39 million. The firm develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It currently has negative earnings. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Excerpt from:
Cesca Therapeutics Inc. (KOOL) Can't Be More Safe. Trades Significantly Higher - Invest Tribune